

FIG. 1




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6

# Experimental Protocol

5TGM1




Figure 7

# Serum IgG<sub>2</sub> levels in 5TGM1-bearing mice




Figure 8

# Tumor Volume in Bone

Treatment/no treatment (%)

n=6-12




Figure 9

# EFFECT OF PS/2 mAb TREATMENT ON SPLEEN WEIGHT




Figure 10

# EFFECT OF PS/2 TREATMENT ON SPLENOCYTES IN MICE WITH 5TGM1 MYELOMA





Figure 11

# EFFECT OF PS/2 mAb TREATMENT ON SPLENOCYTE FACS PROFILE

## DISEASE FREE




File: do111700.077  
Gate: G1  
Total Events: 10707

Acquisition Date: 17-Nov-00  
Gated Events: 9624  
Quad Location: 523, 25

Quad	Events	% Gated	% Total	X Mean	Y Mean
UL	9499	98.70	88.72	37.11	1120.67
UR	3	0.03	0.03	5084.96	773.52
LL	122	1.27	1.14	31.88	11.09
LR	0	0.00	0.00	***	***

## UNTREATED




File: do111700.100  
Gate: G1  
Total Events: 11100

Acquisition Date: 17-Nov-00  
Gated Events: 9526  
Quad Location: 523, 25

Quad	Events	% Gated	% Total	X Mean	Y Mean
UL	4959	52.06	44.68	84.30	1023.41
UR	1388	14.57	12.50	2377.81	704.20
LL	2163	22.71	19.49	50.53	6.64
LR	1016	10.67	9.15	3619.03	4.05

## PS/2 TREATED




File: do111700.120  
Gate: G1  
Total Events: 10934

Acquisition Date: 17-Nov-00  
Gated Events: 9561  
Quad Location: 523, 25

Quad	Events	% Gated	% Total	X Mean	Y Mean
UL	7868	82.29	71.96	58.00	1139.33
UR	310	3.24	2.84	1922.82	897.47
LL	1171	12.25	10.71	42.10	8.17
LR	212	2.22	1.94	3153.17	3.62

## rat IgG2b TREATED



File: do111700.137  
Gate: G1  
Total Events: 10970

Acquisition Date: 17-Nov-00  
Gated Events: 9595  
Quad Location: 523, 25

Quad	Events	% Gated	% Total	X Mean	Y Mean
UL	4910	51.17	44.76	84.95	975.19
UR	1384	14.42	12.62	1937.36	694.49
LL	1704	17.76	15.53	48.67	7.00
LR	1597	16.64	14.56	3286.15	2.68

Figure 12

# EFFECT OF PS/2 mAb TREATMENT ON SPEEN TUMOR BURDEN




Figure 13

# EFFECT OF PS/2 mAB TREATMENT ON BONE MARROW CELLS IN MICE WITH 5TGM1 MYELOMA




Figure 14

EFFECT OF PS/2 TREATMENT ON BONE MARROW TUMOR BURDEN  
mIgG2b POSITIVE CELLS




Figure 15

# EFFECT OF PS/2 mAb TREATMENT ON 5TGM1 CELLS IN THE BLOOD




Figure 16

# EFFECT OF PS/2 TREATMENT ON BLOOD CHEMISTRY




Figure 17

EFFECT OF PS/2 mAb ON  
CIRCULATION mIgG2b LEVELS






Figure 18

# C57/BL/KaLwRaj MULTIPLE MYELOMA MODEL ACUTE TREATMENT PROTOCOLS

1 (200 microgram ) PS/2 TREATMENT / 1 DAY N=3/GROUP



2 (200 microgram ) PS/2 TREATMENTS/ 2 DAYS N=3/GROUP



6 (200 microgram ) PS/2 TREATMENTS/6 DAYS N=5/GROUP




Figure 19

# EFFECT OF PS/2 TREATMENT ON IgG2b POSITIVE CELLS ACUTE TREATMENT MODEL 101E20 659E1660




Figure 20

# EFFECT OF ANTI VLA-4 ANTIBODY PS/2 ON TUMOR BURDEN IN SPLEEN




Figure 21

# EFFECT OF 6 DAYS OF PS/2 TREATMENT




Figure 22

# EFFECT OF 6 DAYS OF PS/2 TREATMENT ON BONE MARROW CELLS




Figure 23



# EFFECT OF TREATMENT ON mIgG2b PLASMA LEVELS




Figure 25

# EFFECT OF TREATMENT ON MYELOMA CELLS AT DAY 27





Figure 26

# EFFECT OF TREATMENT ON TUMOR BURDEN AT DAY 27

## SPLEEN



## BONE MARROW





Figure 27

	Day 20	day 27
	PS/2 Plasma levels	PS/2 Plasma levels
8-PS/2	none detected	none detected
9-PS/2	none detected	none detected
10-PS/2	none detected	none detected
11-melphalan+PS/2	none detected	none detected
12-melphalan+PS/2	3.7 $\mu\text{g/ml}$	none detected
13-melphalan+PS/2	none detected	none detected

**Figure 28**

C57/BIKALwRaj MODEL OF MULTIPLE MYELOMA  
 PS/2 AND ANTI VLA4 SMALL MOLECULE  
 LONG TERM TREATMENT



5TGM1 CELLS (1E6) INJECTED(I.V.) ON DAY 0  
 EFFECTIVNESS OF TREATMENT WAS EVALUATED ON DAY 20

- GROUPS N=2/GROUP
- DISEASE FREE CONTROL
  - UNTREATED MYELOMA CONTROL
  - PS/2 --100 micrograms/injection
  - Sm. Mol . 8809--3 mg/kg, 0.3 mg/kg or 0.03 mg/kg
  - Sm. Mol. 9257 CONTROL -- 3 mg/kg

Figure 29

# EFFECT OF LONG TERM TREATMENT ON MYELOMA CELLS




Figure 30

# EFFECT OF LONG TERM TREATMENT ON TUMOR BURDEN





Figure 31

FOR 2005-2006

C57/BIK<sub>a</sub>LwRaj MODEL OF MULTIPLE MYELOMA  
PS/2 AND ANTI VLA4 SMALL MOLECULE  
ACUTE TREATMENT



5TGM1 CELLS (1E6) INJECTED(I.V.) ON DAY 0  
PS/2 WAS GIVEN ON DAYS 15,16,17,18,19 AND 20  
SMALL MOLECULE WAS GIVEN ON DAYS 15, 16 AND 17  
EFFECTIVNESS OF TREATMENT WAS EVALUATED ON DAY 21

GROUPS N=2/GROUP  
DISEASE FREE CONTROL  
UNTREATED MYELOMA CONTROL  
PS/2 --100 micrograms/injection  
8809--3 mg/kg, 0.3 mg/kg or 0.03 mg/kg  
9257 CONTROL -- 3 mg/kg

Figure 32

# EFFECT OF ACUTE TREATMENT ON MYELOMA CELLS




Figure 33

# EFFECT OF ACUTE TREATMENT ON TUMOR BUREN




Figure 34

# Experimental Protocol

5TGM1 Cells ( $10^6$ /mouse)



Day	0	1	7	14	21	28
-----	---	---	---	----	----	----

Ab/mouse	↑	↑	↑	↑	↑	↑
			200 $\mu$ g i.p.		80 $\mu$ g i.p.	

Melphalan/mouse	↑		↑		↑	
			100 $\mu$ g i.p.			

Figure 35

# Inhibition of Hindleg Paralysis




Figure 36